About Us
Technology
History
StemInov is a clinical stage company, spin-off from Nancy’s Teaching Hospital and Lorraine Region’s Uni.
The company develops an off-the-shelf, allogenic stem cell therapy treatment, in the field of inflammatory pathologies, with a focus on critical care.
The company's lead product candidate “WhartSep” is based on Stem cells from Wharton jelly of the umbilical cord (WJ-MSC) an ATMP (Advanced-Therapy Medicinal Product).
WhartSep is a new concept in immunomodulation and adaptive medicine thanks to its immunomodulation properties.
Our first indication is the patented treatment of severe pneumonia in entry of phase Ib/IIa
Management Team
CEO
Co-Founder
Julie
HUTIN
Ecole Centrale Lyon
Master EM Lyon
HEC Challenge + 2020-2
5y experience in Eurofins Genomics
Scientific Founder
Danièle
BENSOUSSAN
PU-PH - Head of Cellular Therapy Unit and Tissue Banking, Cord Blood Banking (UTCT)
Head of a CNRS Team
Lead to the patent operated by StemInov
72 Publications in ATMP over the last 12 yrs
